Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

CNSYAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ722.18+ 1.40%S&P 500 · SPY769.66+ 0.56%Dow Jones · DIA523.28+ 0.06%Russell 2000 · IWM280.18+ 1.15%

Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence today announced that a poster presentation of interim
Benzinga03:3318 Hours AgoCNSY+5.7%

04:00Oct 231 Story

How Much Downside Is Left In Moderna Stock?
For questions about this article or underlying research, email help@trefis.com.
Yahoo04:00

06:00Oct 221 Story

New Strong Sell Stocks for October 22nd
CANG, CDZI and CNSY have been added to the Zacks Rank #5 (Strong Sell) List on October 22, 2026.
Yahoo06:53CNSY+5.7%

03:00-08:00Oct 212 Stories

Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Findings suggest a dual mechanism of action for REYOBIQ against cancer cells New findings revealed potential dual mechanism as combinations with checkpoint blockade further enhanced REYOBIQ therapeutic action in multiple cancers HOUSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of
Yahoo07:30CNSY+5.7%
Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ
Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging
Benzinga03:31

03:00Oct 151 Story

New Strong Sell Stocks for October 15th
CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.
Yahoo03:47CNSY+5.7%

17:00Oct 121 Story

Where Could Moderna's Next Growth Come From?
Moderna (MRNA) stock has returned 621% over the past twelve months, easily outpacing the S&P 500's 17.0% return. Yet the company's sales have fallen for three consecutive years, and nearly all of that revenue still comes from COVID vaccines. This divergence suggests investors are placing heavy bets on a product Moderna does not sell yet. So what is Moderna getting ready to sell, and how far along is it.
Yahoo17:01

CNSY▲+5.7%